Novel strategies leverage baseline TCR diversity (3) and spatial CD8+ TIL patterns, including associated with prognosis in stage I–IIIA NSCLC (33) and tumor nest localization observed in stage IV disease (34). The gene discussed is CD8A; the disease is neoplasm.